Benefits
Improved oxidative stress markers in one type 2 diabetes trial
In a 12-week double-blind trial in 80 adults with type 2 diabetes on metformin, Capros 250 or 500 mg twice daily lowered malondialdehyde and raised glutathione versus placebo; malondialdehyde fell 28% on the 500 mg dose. CRP also fell when five randomized trials of amla were pooled. Laboratory antioxidant scores such as ORAC do not predict what happens in a person.
Better cholesterol and triglyceride readings in randomized trials
A meta-analysis of five randomized controlled trials found amla significantly lowered total cholesterol, LDL and triglycerides and raised HDL in adults aged about 40 to 58. In a separate 42 day trial without a placebo group, 40 adults with high cholesterol taking 500 mg a day of amla juice powder had lower total cholesterol, LDL and triglycerides and higher HDL than at the start. Amla is not a replacement for cholesterol medication.
Lower fasting blood sugar in randomized trials
Across the five randomized trials pooled in the meta-analysis, amla significantly lowered fasting blood glucose. Post-meal glucose and insulin sensitivity were not analyzed, and proposed mechanisms come from laboratory and animal work. The pooled adults were aged about 40 to 58 with an average BMI of 25.5, so effects in other groups may differ. Amla is not a treatment for diabetes and should not replace prescribed medication.
Less frequent and milder heartburn and regurgitation in one trial
In a double-blind trial, 68 people with reflux symptoms for at least 3 months and a normal endoscopy took two 500 mg amla tablets or placebo twice daily after meals for 4 weeks. Symptoms eased in both groups, but heartburn and regurgitation frequency and severity fell more with amla. The tablets were made by a university pharmacy faculty, not Capros. One small, short trial, registered after it started.
Mechanism of action
Emblicanin tannins and vitamin C release (proposed)
Emblicanins are hydrolyzable tannins that are thought to break down in the gut and release gallic acid and related compounds; this was not measured in the cited trials. A slow release vitamin C effect is often described for amla, but none of the studies cited here measured vitamin C levels in the blood or compared amla against plain vitamin C, so the timing figures sometimes quoted for this are unverified.
Anti-inflammatory pathways (proposed, from laboratory work)
Laboratory work has proposed that gallic acid and ellagic acid from amla act on inflammation signalling (NF-kB) and on Nrf2, which switches on the body's own antioxidant enzymes; no cited human trial tested this. What the trials did show is that CRP, a blood marker of inflammation, fell significantly when five randomized trials were pooled. IL-6, TNF-alpha and antioxidant enzyme levels were not measured.
Clinical trials
Randomized, double-blind, placebo-controlled 4-arm study: Capros® amla extract 250 mg or 500 mg twice daily, atorvastatin 10 mg/day, or placebo for 12 weeks. Primary outcome: endothelial function (reflection index on salbutamol challenge). Secondary: oxidative stress markers, hsCRP, lipids, HbA1c. Natreon supplied the extract and placebo. (Usharani et al. 2013, Diabetes Metab Syndr Obes)
80 adults aged 30 to 68 with type 2 diabetes on stable metformin (20 per group). 12-week intervention.
All three active treatments improved endothelial function versus baseline and placebo. Versus placebo, malondialdehyde fell 28% on Capros 500 mg and 30% on atorvastatin, and hsCRP fell 63% and 65%; atorvastatin lowered cholesterol more (total 24.68% vs 14.3%, LDL 35% vs 20.15%). HbA1c fell versus placebo on 500 mg but not 250 mg. Dyspepsia in 3 people on 500 mg; none stopped.
Comparative parallel clinical trial (randomization and blinding not described): amla 500 mg/day (a dried amla fruit juice powder from Pharma Intel Co, not identified as Capros) for 42 days vs simvastatin 20 mg/day in 60 patients with type II hyperlipidemia (TC >240 mg/dL, LDL >130 mg/dL). 40 received amla, 20 simvastatin. No placebo group. (Gopa et al. 2012, Indian J Pharmacol)
60 adults aged 35 to 65 with type II hyperlipidemia, 38 of them with high blood pressure. 42-day comparison.
Amla significantly lowered total cholesterol, LDL, triglycerides and VLDL and raised HDL versus baseline. The authors called the lipid changes nearly equivalent to simvastatin 20 mg, except that simvastatin lowered triglycerides and VLDL significantly more. Blood pressure improved in 21 of 28 hypertensive patients on amla and 6 of 10 on simvastatin. No adverse effects were reported. Small, 42 days, no placebo.
Double-blind, randomized, placebo-controlled parallel trial: two 500 mg amla tablets or matching placebo twice daily after meals for 4 weeks. Symptom frequency and severity scored at baseline, week 2 and week 4. Tablets made by the Faculty of Pharmacy, Tehran University of Medical Sciences (not Capros); university-funded; registered retrospectively (IRCT2016061428469N1). (Karkon Varnosfaderani et al. 2018, J Integr Med)
68 patients with heartburn, regurgitation and upper abdominal pain for at least 3 months and a normal endoscopy (non-erosive reflux); per the registry, randomized if symptoms persisted after a 2-week anti-reflux diet. 4-week intervention.
Heartburn and regurgitation frequency fell in both groups. Over the study, regurgitation frequency, heartburn frequency, regurgitation severity and heartburn severity fell significantly more with amla than with placebo (P < 0.001). The abstract reports no safety data. One small, short trial.